


PF-03463275

Cat. No.:	HY-10716A		
CAS No.:	1173239-39-8		
Molecular Formula:	C ₁₉ H ₂₂ ClFN ₄ O		
Molecular Weight:	376.86		
Target:	GlyT		
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 33.33 mg/mL (88.44 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.6535 mL	13.2675 mL	26.5351 mL
		5 mM	0.5307 mL	2.6535 mL	5.3070 mL
10 mM		0.2654 mL	1.3268 mL	2.6535 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.83 mg/mL (2.20 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.83 mg/mL (2.20 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.83 mg/mL (2.20 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	PF-03463275 is a centrally penetrant, orally available, selective, and competitive GlyT1 (glycine transporter-1) reversible inhibitor, with a K _i of 11.6 nM. PF-03463275 has the potential for Schizophrenia research ^{[1][2]} .
In Vivo	PF-03463275 (1-10 mg/kg; s.c.) attenuates oscillatory potentials (OPs) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats ^[2]
Dosage:	1, 3 and 10 mg/kg
Administration:	S.c.
Result:	A dose-dependent reduction in the amplitude of oscillatory potentials (OPs) elicited from the dark-adapted rats.

REFERENCES

[1]. Lowe JA 3rd, et al. The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter [published correction appears in Bioorg Med Chem Lett. 2009 Aug 15;19(16):4885. Bronk, Brian S [added]; Schaeffer, Eric [added]]. Bioorg Med Ch

[2]. Liu CN, Pettersen B, Seitis G, Osgood S, Soms C. GlyT1 inhibitor reduces oscillatory potentials of the electroretinogram in rats. Cutan Ocul Toxicol. 2014;33(3):206-211.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA